Cardiocutaneous syndromes are rare, genetically determined disorders in which arrhythmogenic cardiomyopathy is accompanied by characteristic cutaneous phenotypes of woolly hair and palmoplantar keratoderma. Pattern of cardiac involvement differs in different cardiocutaneous syndromes; right ventricle (RV) is predominantly affected in the form of classical arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) in Naxos disease whereas the left ventricle (LV) is mainly involved in the form of dilated cardiomyopathy in Carvajal syndrome. Both conditions are transmitted in autosomal recessive manner, and results from mutations in cell adhesion molecules compromising the integrity of desmosomal junctions of skin and myocardium. Naxos disease usually presents by adolescence with malignant ventricular arrhythmia or cardiac arrest whereas Carvajal syndrome is manifested earlier with heart failure. Cardiomyopathy is diagnosed by the 2010 Task Force Criteria. Implantation of automated implantable cardioverter-defibrillator (AICD) forms the mainstays of treatment by preventing sudden cardiac death. Genetic testing is available. Several international databases and registries, often as a part of other genetically determined arrhythmogenic disorders, are directed to better characterize and manage these cardiocutaneous syndrome patients.
Palmoplantar keratoderma is characterized by thickening of the skin on the palms and soles. This feature is not present at birth, rather develops during the first year of life when the infant starts using the hands and feet [19]. Palmoplantar keratoderma of Naxos disease and Carvajal syndrome is of striate type, however, is not specific to them, and can be seen in other acquired and inherited conditions (Figure 2).

Cardiomyopathy is the most clinically important feature of Naxos disease and Carvajal syndrome. The cardiomyopathy of both the conditions constitutes the relatively rare, recessively-transmitted variant of ARVC/D, which can affect either ventricle. In Naxos disease, the RV is affected, and usually presents by adolescence with arrhythmia manifested as syncope and/or ventricular tachycardia (VT) of left bundle branch block (LBBB) morphology. In contrast, in case of Carvajal syndrome, the LV is predominantly affected, the presentation is in earlier ages, may be in childhood, and the usual presentation is heart failure rather than arrhythmia. Presence of myocardial non-compaction [29] and absence of significant myocardial fibro-fatty replacement [30], also differentiate cardiomyopathy in Carvajal syndrome from that in Naxos disease.

**Diagnosis**

The diagnosis of Naxos disease and Carvajal syndrome is often straight forward in presence of telltale features usually in childhood or adolescence. Woolly hair and palmoplantar keratoderma are recognized clinically. No single diagnostic test exists for ARVC/D. The diagnosis is made using a combination of clinical, electrocardiographic and radiological features, as defined by the 2010 Task Force Criteria (TFC) [31].

Electrocardiograms (ECGs), echocardiography and cardiac magnetic resonance (CMR) are the investigations commonly done for diagnosis and evaluation of ARVC/D. ECG findings...
usually are the first clinical abnormalities recognized in patients suspected of ARVC/D. The classic ECG findings in ARVC/D are inverted T waves in the right precordial leads (V1-V3) with an epsilon wave just after the QRS in lead V1 [32]. Complete and incomplete right bundle branch block (RBBB) may also be observed [33,34]. The epsilon waves are reproducible small deflections seen just beyond the QRS complex in lead V1 or V2. (Figure 3). Signal–averaged ECG (SAECG) may show late potentials. An abnormal SAECG is supportive of the diagnosis of ARVC/D but a negative test does not exclude this diagnosis. Holter ECG assists with the diagnosis when there are frequent ventricular extra–systoles, (>1,000 per 24 h) usually of LBBB morphology. Ventricular tachycardia (VT) occurring in ARVC/D patients originate in the RV, is of LBBB morphology and has either an inferior or superior QRS axis [35]. The major differential diagnosis of VT of LBBB morphology with inferior QRS axis (negative QRS in lead aVL) is relatively benign right ventricular outflow tract (RVOT) tachycardia. Patients with RVOT tachycardia do not usually have the ECG abnormalities associated with ARVC/D and the SAECG is generally normal.

Echocardiography and CMR detect structural and functional abnormalities of RV or LV or both. A transthoracic echocardiography (TTE) examination is an ideal screening tool to assess ventricular size and function in patients with possible ARVC/D or LV cardiomyopathy. In case of ARVC/D, the TTE features include RV dilatation, aneurysm formation, and global or regional hypokinesia mainly in the sub–tricuspid region, RVOT and RV apex [36]. Echocardiography is sensitive for ARVC/D, but it is not specific, because it does not allow for an assessment of the adipose substitution of the myocardium, which is a hallmark of ARVC/D. Echocardiography is less sensitive than CMR, because it may fail to depict focal RV wall thickening, and it does not reliably help in distinguishing fat from muscle. Three–dimensional (3D) echocardiography, contrast echocardiography, tissue–Doppler imaging, strain–rate imaging may play role in future. In case of Carvajal syndrome, echocardiographic features include dilated cardiomyopathy, may be having features of non–compaction predominantly affecting the LV.

CMR is the non–invasive tool of choice; it enables good assessment of cardiac morphology and function while also allowing flow dynamic studies and tissue characterization. CMR findings associated with ARVC/D include RV wall thinning, RVOT enlargement, trabecular disarray, fibrofatty replacement, ventricular dilatation, and global or regional systolic dysfunction [37–39]. These abnormalities typically occur in predilection sites including the RV base and LV lateral wall. Like RV evaluation, CMR is useful in evaluation of LV cardiomyopathy in Carvajal syndrome as well. The CMR picture of Carvajal syndrome often mimics that of LV non–compaction [30].

Cardiac computed tomography (CT) scanning is not included in the 2010 TFC for ARVC/D. However, a possible use of CT lies in the evaluation of claustrophobic patients, assessment of subjects with frequent ventricular extra–systoles leading to severe arrhythmia artifacts on CMR, serial evaluation of automated implantable cardioverter–defibrillator (AICD) carriers, and before ablation procedures [40,41].

Electrophysiological studies are not included in the 2010 TFC, but may be important for differential diagnosis from RVOT tachycardia. Ventriculography, endomyocardial biopsy and genetic testing may be indicated in selected cases.

**Treatment**

Like ARVC/D, the most important goals of clinical management of Naxos disease and Carvajal syndrome patients comprise: reduction of mortality, either by arrhythmic sudden death or death due to heart failure; prevention of disease progression leading to RV, LV or biventricular dysfunction and heart failure; attenuation of symptoms and improvement of quality of life by decreasing or suppressing palpitations, VT recurrences or AICD discharges; and reducing heart failure symptoms and increasing exercise capacity. Life–style modifications, pharmacologic treatment, catheter ablation, AICD implantation, and exceptionally heart transplantation are the management options. In case of Naxos disease, syncope, LV involvement and the appearance of symptoms and/or structural progression before the age of 35 years were risk factors for sudden death [20]. Sustained or non–sustained VT and decreased LV function have recently been identified as risk factors for subsequent arrhythmic death in patients with ARVC/D [42]. Endocardial voltage mapping (EVM) has been found to be useful in stratifying the arrhythmia risk in ARVC/D patients. The extent of negative T–waves across the 12–lead ECG was found to correlate with the amount of RV–electroanatomic scar (RV–EAS) and predict EAS–related arrhythmic risk [43]. Also, the extent of bipolar RV endocardial low–voltage area detected by EVM was shown to be a powerful predictor of arrhythmic outcome in ARVC/D, independently of history and RV dilatation/dysfunction; a normal bipolar EVM characterized a low–risk subgroup of ARVC/D patients [44]. Anti–arrhythmics like sotalol and amiodarone are used. However, AICD implantation is the most effective strategy for interruption of potentially lethal ventricular tachy–arrhythmias in cardiocutaneous syndrome. For ARVC/D, there is general agreement that patients with a history of cardiac arrest or hemodynamically unstable VT are at high risk of sudden cardiac death and needs an AICD, however, indications for

![Figure 3: Epsilon wave in ECG (marked by the arrow).](image)
primary prevention remain a matter of debate [45]. For Naxos disease and Carvajal syndrome, AICD is probably indicated in those who develop symptoms and/or structural progression before the age of 35 years [17,20,46,47]. Anti-arrhythmic drugs are used as an adjunct after AICD implantation. The wearable cardioverter-defibrillators (WCDs) may have a role as a bridging therapy before the scheduled AICD implantation or heart transplantation in Naxos disease and Carvajal syndrome [48,49].

Diuretics and angiotensin converting enzyme inhibitors are indicated in heart failure, anti-thrombotics may prevent thrombus formation in high-risk patients. Heart transplantation remains the only option for the end-stage cardiomyopathy patients [12]. Ventricular assist device (VAD) has been used before cardiac transplantation in a patient with Carvajal syndrome [50]. Emollients, topical keratolytics, tazarotene 0.05%, and tretinoin 0.1% can be tried for palmoplantar keratoderma [51].

Prevention

So far, 13 disease genes have been identified, responsible for around 60% of all ARVC/D cases [52]. Most of mutations in dominant forms have been identified in desmosomal genes including DSP, plakophilin–2 (PKP2), desmoglein–2 (DSG2), desmocollin–2 (DSC2) and JUP [53]. Being genetic diseases, ARVC/D is at present incurable. So, early detection and prevention may be attractive options. Clinical genetic testing is already available worldwide for the common ARVC/D-associated genes, e.g., plakophilin–2 (PKP2), desmoplakin (DSP), desmoglein–2 (DSG2), desmocollin–2 (DSC2), plakoglobin (JUP), transmembrane protein 43 (TMEM43), ryanodine receptor 2 (RYR2) [54]. However, genotyping success rate in ARVC/D varies according to cohort location and ethnicity, sequencing techniques, selection criteria and the stringency of the standards by which mutations are considered causal [53]. Thus, genetic testing and its interpretation should be performed in dedicated ARVC/D cardio–genetic centers, with pre- and post-counseling facilities. A negative genetic test does not exclude a genetic predisposition.

In an attempt to control Naxos disease, systematic genetic screening of the populations at risk has been carried out to identify the heterozygous carriers of the plakoglobin gene mutation [1]. Several registries are dealing with ARVC/D patients around the globe. A multidisciplinary collaborative European study has been designed with the aim to investigate the clinical, pathological and genetic features of ARVC/D [55]. One of the missions is the study of Naxos disease (participating unit: Yannis Protonotarios Medical Center, Naxos, Greece). Simultaneously, another major registry in North America worked in collaboration with European expertise [56]. The Johns Hopkins Arrhythmogenic Right Ventricular Dysplasia (Cardiomyopathy) Program of USA [54], the Australian Genetic Heart Disease Registry [57], the Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Program at the University Hospital Zurich [58] and the Canadian Arrhythmogenic Right Ventricular Cardiomyopathy Registry [59], are also active.

Conclusion

The liaison between skin and heart may be dangerous. The clinicians should have appropriate preparedness to recognize the rare but often lethal cardiocutaneous syndromes including Naxos disease and Carvajal syndrome. Any child presenting with woolly hair at birth should be evaluated and followed up regularly. The mainstay of treatment is to prevent sudden cardiac death. AICD should be offered to the high risk cases. Early diagnosis, proper risk stratification, timely treatment, and regular follow up can lessen the morbidity and mortality of the patients.

References

1. Protonotarios N, Tsatsopoulou A (2006) Naxos disease: cardiocutaneous syndrome due to cell adhesion defect. Orphanet J Rare Dis 1: 4. Link: https://goo.gl/60eWu
2. Simpson MA, Mansour S, Alnood D, Kalidas K, Patton MA, et al. (2009) Homozygous mutation of desmocollin-2 in arrhythmogenic right ventricular cardiomyopathy with mild palmoplantar keratoderma and woolly hair. Cardiology 113: 28-34. Link: https://goo.gl/rdz9bX
3. Awad MM, Dalal D, Tichnell C, James C, Tucker A, et al. (2006) Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation in PKP2. Hum Mutat 27: 1157. Link: https://goo.gl/36XacB
4. Protonotarios N, Tsatsopoulou A. (2004) Naxos disease and Carvajal Syndrome: cardiocutaneous disorders that highlight the pathogenesis and broaden the spectrum of arrhythmogenic right ventricular cardiomyopathy. Cardiovasc Pathol 13: 185-194. Link: https://goo.gl/36XacB
5. McCoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, et al. (2000) Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 355: 2119-2124. Link: https://goo.gl/8Foj2X
6. Norrett EE, Hatzell SJ, Carvajal-Huerta L, Cabezas JC, Common J, et al. (2000) Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum Mol Genet 9: 2761-2766. Link: https://goo.gl/UXj2hJ
7. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, et al. (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93(5):841-842. Link: https://goo.gl/3RYG6i
8. Protonotarios N, Tsatsopoulou A, Patsourakos P, Alexopoulos D, Gezerlis P, et al. (1996) Cardiac abnormalities in familial palmoplantar keratosis. Br Heart J 56: 321-326. Link: https://goo.gl/lyHkwW
9. Islam AM, Rahman MT, Chowdhury AH. (2016) Cardiocutaneous syndrome (Naxos disease) in a Bangladeshi boy. Cardiovasc Diagn Ther 6: 462-465. Link: https://goo.gl/vlUKcX
10. Saravanan RR, Amuthan V, Janarthanan RA, Balasubramanian S, Mohamed SN. (2012) A case of arrhythmogenic right ventricular cardiomyopathy-Naxos disease. Indian Heart J 64: 84-87. Link: https://goo.gl/1UAHDA
11. Bukhari I, Juma’a N (2004) Naxos disease in Saudi Arabia. J Eur Acad Cardiology 113: 28-34. Link: https://goo.gl/lyHkwW
12. Narin N, Akcakus M, Gunes T, Celiker A, Baykan A, et al. (2003) Arrhythmogenic right ventricular cardiomyopathy (Naxos disease): report of a Turkish boy. Pacing Clin Electrophysiol 26: 2326-2329. Link: https://goo.gl/TEys9b
13. Djabali K, Martínez-Mir A, Horev L, Christiano AM, Zlotogorski A (2002) Evidence for extensive locus heterogeneity in Naxos disease. J Invest Dermatol 118: 557-560. Link: https://goo.gl/h77B09
45. Zorzi A, Rigato I, Bauce B, Pilichou K, Basso C, et al. (2016) Arrhythmogenic right ventricular cardiomyopathy: Risk stratification and indications for defibrillator therapy. Curr Cardiol Rep 18: 57. Link: https://goo.gl/7T0Vwf

46. Gatzoulis K, Protonotarios N, Anastasakis A, Tsatsopoulou A, Vlasserou J, et al. (2000) Implantable defibrillator therapy in Naxos disease. Pacing Clin Electrophysiol 23: 1176-1178. Link: https://goo.gl/nKWWG3

47. Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, et al. (2003) Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 108: 3084-3091. Link: https://goo.gl/H5jaP4

48. Piccini JP Sr, Allen LA, Kudenchuk PJ, Page RL, Patel MR, et al. (2016) Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death: A Science Advisory From the American Heart Association. Circulation 133: 1715-1727. Link: https://goo.gl/D20zOl

49. Wäßnig NK, Günther M, Quick S, Pfluecke C, Rottstädt F, et al. (2016) Experience with the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. Circulation 134: 635-643. Link: https://goo.gl/Rqjhz

50. Bottio T, Bejkoe J, Tarzia V, Gerosa G. (2014) HeartWare LVAD implantation in a patient with a rare ARVD: Carvajal syndrome. Int J Artif Organs 37: 563-566. Link: https://goo.gl/XnijXc

51. Srinivas SM, Kumar P, Basavaraja GV (2016) Carvajal syndrome. Int J Trichology 8: 53-55. Link: https://goo.gl/LQKwFy

52. Poloni G, De Bortoli M, Calore M, Rampazzo A, Lorenzon A (2016) Arrhythmogenic right-ventricular cardiomyopathy: molecular genetics into clinical practice in the era of next generation sequencing. J Cardiovasc Med (Hagerstown) 17: 399-407. Link: https://goo.gl/8IjC7q

53. Pilichou K, Thiene G, Bauce B, Rigato I, Lazzarini E, et al. (2016) Arrhythmogenic cardiomyopathy. Orphanet J Rare Dis 11: 33. Link: https://goo.gl/XBvOUh

54. The Johns Hopkins Arrhythmogenic Right Ventricular Dysplasia (Cardiomyopathy) Program. Heart & Vascular Institute. John Hopkins Medicine Link: https://goo.gl/2b3YEC

55. Basso C, Wichter T, Danieli GA, Corrado D, Czarnowska E, et al. (2004) Arrhythmogenic right ventricular cardiomyopathy: clinical registry and database, evaluation of therapies, pathology registry, DNA banking. Eur Heart J 25: 531-534. Link: https://goo.gl/3NsWNT

56. Marcus F, Towbin JA, Zareba W, Moss A, Calkins H, et al. (2003) Arrhythmogenic right ventricular dysplasia/cardiomypathy (ARVD/C): a multidisciplinary study: design and protocol. Circulation 107: 2975-2978. Link: https://goo.gl/5H41LB

57. The Australian Genetic Heart Disease Registry. Link: https://goo.gl/12Dh8d

58. Zurich ARVC Program. Link: https://goo.gl/7qKsxS

59. Krahn AD, Healey JS, Gerull B, Angaran P, Chakrabarti S, et al. (2016) The Canadian Arrhythmogenic Right Ventricular Cardiomyopathy Registry: Rationale, design, and preliminary recruitment. Can J Cardiol 32: 1396-1401. Link: https://goo.gl/kkTCjl

Copyright: © 2017 Islam AKMM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Islam AKMM, Khan A, Hossain Z (2017) Cardiocutaneous Syndrome: The Tale between Heart and Skin. Glob J Rare Dis 2(1): 001-006.